Immuron Ltd ADR IMRN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IMRN is a good fit for your portfolio.
News
-
Immuron to host Live Virtual Event
-
Immuron Travelan® sales continued strong growth
-
Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US
-
Immuron Presentation Australian Biologics Festival 2024
-
Immuron achieves record Travelan® sales
-
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
-
PacWest leads regional bank rally. Berkshire Hathaway, Dish, AMC, Tyson and other stocks on the move.
-
Immuron Shares Hit 52-Week High After FDA Removes Clinical Hold
Trading Information
- Previous Close Price
- $2.46
- Day Range
- $2.43–2.52
- 52-Week Range
- $1.48–5.96
- Bid/Ask
- $2.14 / $2.49
- Market Cap
- $14.18 Mil
- Volume/Avg
- 333 / 1.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.24
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 6
- Website
- https://www.immuron.com.au
Valuation
|
Metric
|
IMRN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.24 |
Price/Sales | 6.24 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
IMRN
|
|---|---|
Quick Ratio | 7.63 |
Current Ratio | 8.52 |
Interest Coverage | −446.38 |
Quick Ratio
IMRN
Profitability
|
Metric
|
IMRN
|
|---|---|
Return on Assets (Normalized) | −17.91% |
Return on Equity (Normalized) | −19.92% |
Return on Invested Capital (Normalized) | −20.86% |
Return on Assets
IMRN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Kkdszsms | Bfghw | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lsypffl | Srpdqs | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bfhdsqbnc | Dznlr | $99.5 Bil | |
MRNA
| Moderna Inc | Yycsxfgc | Bzpy | $38.8 Bil | |
ARGX
| argenx SE ADR | Ftcchbmjb | Jxcct | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Zptgntdw | Cysvq | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hzcmjskf | Fsvhwv | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dnclfymh | Rhvkfc | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lgmprxbkh | Systr | $12.5 Bil | |
INCY
| Incyte Corp | Sswggllf | Thsxqkd | $11.6 Bil |